{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:39:48Z","timestamp":1792269588715,"version":"4.4.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sutimlimab, an anti-C1s monoclonal antibody, is approved for the treatment of cold agglutinin disease (CAD). It prevents hemolysis by inhibiting the classical complement pathway. One of its off-target effects may be increasing circulatory complications that have not yet been characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We report two patients with CAD who developed unusual widespread skin cyanosis and exacerbated acrocyanosis during sutimlimab treatment. One of the two patients additionally experienced massive intravascular hemolysis, eryptosis and acute renal failure. Serological analyses were conducted using standard techniques, and eryptosis was quantified by flow cytometry with PE-labelled Annexin V.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Serological assays using plasma and serum from these two patients and four additional untreated patients (n=6) with CAD were performed. They demonstrated a significant increase in red blood cell (RBC) agglutination in the presence of sutimlimab as well as in the absence of complement activation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The observed increase in RBC agglutination under sutimlimab treatment is likely due to a substantial reduction of C3d deposition on RBCs. This mechanism also represents the most plausible explanation for the side effects observed in some patients with CAD receiving the drug, such as aggravation of circulatory complications, including acrocyanosis, Raynaud\u2019s phenomenon, and less commonly, organ dysfunction. Inhibition of early complement components (C1-C3) may therefore not only prevent hemolysis in CAD but paradoxically also promote RBC agglutination, eryptosis, and hemolysis in certain cases. Pre-treatment serological testing with sutimlimab may help predict some of these adverse effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1906515","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:35:50Z","timestamp":1789450550000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Complement inhibition by sutimlimab in cold agglutinin disease promotes red blood cell agglutination and may lead to circulatory complications, eryptosis and hemolysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Thilo","family":"Bartolm\u00e4s","sequence":"first","affiliation":[{"name":"Institute of Transfusion Medicine, Charit\u00e9-Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Mayer","sequence":"additional","affiliation":[{"name":"Institute of Transfusion Medicine, Charit\u00e9-Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulgabar","family":"Salama","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Charit\u00e9-Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu","place":["Berlin, Germany"]},{"name":"Haemostaseologicum Medicover","place":["Berlin, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"B1","volume-title":"The Haemolytic Anaemias Part Ii the Auto-Immune Haemolytic Anaemias","author":"Dacie","year":"1962"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1172\/jci105764","article-title":"Chronic hemolytic anemia due to cold agglutinins: the mechanism of resistance of red cells to C' hemolysis by cold agglutinins","volume":"46","author":"Evans","year":"1967","journal-title":"J Clin Invest"},{"key":"B3","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1001\/archinte.1946.00210400069006","article-title":"Chronic hemolytic anemia due to cold agglutinins. II. The role of C' in red cell destruction","volume":"47","author":"Evans","year":"1968","journal-title":"J Clin Invest"},{"key":"B4","first-page":"XX","volume-title":"Immune Hemolytic Anemias","author":"Petz","year":"2004"},{"key":"B5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1749-6632.1965.tb18982.x","article-title":"The cold hemagglutinin disease","volume":"3","author":"Schubothe","year":"1966","journal-title":"Semin Hematol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084296","article-title":"Autoimmune hemolytic anemias: classifications, pathophysiology, diagnoses and management","volume":"25","author":"Loriamini","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1182\/hematology.2025000718","article-title":"Diagnosis and management of cold agglutinin disease","volume":"2025","author":"Berentsen","year":"2025","journal-title":"Hematol \/ Educ Program Am Soc Hematol Am Soc Hematol Educ Program"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2024.2372333","article-title":"The impact of individual clinical features in cold agglutinin disease: hemolytic versus non-hemolytic symptoms","volume":"17","author":"Berentsen","year":"2024","journal-title":"Expert Rev Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system Part I - molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441406","article-title":"Complement. First of two parts","volume":"344","author":"Walport","year":"2001","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2012.01.002","article-title":"Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia","volume":"26","author":"Berentsen","year":"2012","journal-title":"Blood Rev"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.blre.2007.08.002","article-title":"Cold antibody autoimmune hemolytic anemias","volume":"22","author":"Petz","year":"2008","journal-title":"Blood Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1983.tb01234.x","article-title":"Deposition of the terminal C5b-9 complement complex on erythrocytes by human red cell autoantibodies","volume":"55","author":"Salama","year":"1983","journal-title":"Br J Haematol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/ejh.12976","article-title":"Eryptosis in autoimmune haemolytic anaemia","volume":"100","author":"Bartolm\u00e4s","year":"2018","journal-title":"Eur J Haematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12976","article-title":"Sublytic terminal complement components induce eryptosis in autoimmune haemolytic anaemia related to IgM autoantibodies","volume":"53","author":"Balola","year":"2019","journal-title":"Cell Physiol Biochem"},{"key":"B16","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/s10495-023-01915-4","article-title":"Apoptosis and eryptosis: similarities and differences","volume":"29","author":"Tkachenko","year":"2024","journal-title":"Apoptosis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cells11030503","article-title":"Eryptosis: programmed death of nucleus-free, iron-filled blood cells","volume":"11","author":"Dreischer","year":"2022","journal-title":"Cells"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2017.06.001","article-title":"Eryptosis in health and disease: a paradigm shift towards understanding the (patho)physiological implications of programmed cell death of erythrocytes","volume":"31","author":"Qadri","year":"2017","journal-title":"Blood Rev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.226","article-title":"Cold agglutinin disease","volume":"2016","author":"Berentsen","year":"2016","journal-title":"Hematol \/ Educ Program Am Soc Hematol Am Soc Hematol Educ Program"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-474437","article-title":"Cold agglutinin disease","volume":"122","author":"Swiecicki","year":"2013","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"689","DOI":"10.4049\/jimmunol.2300630","article-title":"Inhibition of the C1s protease and the classical complement pathway by 6-(4-phenylpiperazin-1-yl)pyridine-3-carboximidamide and chemical analogs","volume":"212","author":"Xu","year":"2024","journal-title":"J Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1015128","article-title":"Complement C1s as a diagnostic marker and therapeutic target: progress and propective","volume":"13","author":"Ye","year":"2022","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1182\/blood.2023022549","article-title":"Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia","volume":"145","author":"Roman","year":"2025","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.70147","article-title":"Iptacopan for immune thrombocytopenia and cold agglutinin disease: a global phase 2 basket clinical trial","volume":"101","author":"R\u00f6th","year":"2026","journal-title":"Am J Hematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1672590","article-title":"Iptacopan for cold agglutinin disease: a case report with literature review","volume":"16","author":"Fang","year":"2025","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027760","article-title":"Sutimlimab in cold agglutinin disease","volume":"384","author":"R\u00f6th","year":"2021","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26965","article-title":"Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease","volume":"98","author":"R\u00f6th","year":"2023","journal-title":"Am J Hematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014955","article-title":"Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial","volume":"140","author":"R\u00f6th","year":"2022","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009318","article-title":"Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up","volume":"7","author":"R\u00f6th","year":"2023","journal-title":"Blood Adv"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-024-03842-9","article-title":"Long-term safety profile of sutimlimab in adult Japanese patients with cold agglutinin disease","volume":"120","author":"Miyakawa","year":"2024","journal-title":"Int J Hematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2024.15.6.4","article-title":"Sutimlimab for cold agglutinin disease","volume":"15","author":"Reid","year":"2024","journal-title":"J Adv Pract Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"102733","DOI":"10.1016\/j.eclinm.2024.102733","article-title":"Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B","volume":"74","author":"R\u00f6th","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2026033150","article-title":"Sutimlimab vs B-cell-targeted therapy in cold agglutinin disease: which is the optimal approach","volume":"147","author":"Fattizzo","year":"2026","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01805.x","article-title":"Mixed-type autoimmune hemolytic anemia: differential diagnosis and a critical review of reported cases","volume":"48","author":"Mayer","year":"2008","journal-title":"Transfusion"},{"key":"B36","first-page":"899","volume-title":"Technical Manual","author":"Cohn","year":"2023"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1114509","DOI":"10.3389\/fimmu.2023.1114509","article-title":"Three different pathways of IgM-antibody-dependent hemolysis are mainly regulated by complement","volume":"14","author":"Bartolm\u00e4s","year":"2023","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026575","article-title":"Refractoriness of eryptotic red blood cells to Plasmodium falciparum infection: a putative host defense mechanism limiting parasitaemia","volume":"6","author":"Totino","year":"2011","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003809","article-title":"How I treat cold agglutinin disease","volume":"137","author":"Berentsen","year":"2021","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"100648","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting","volume":"41","author":"J\u00e4ger","year":"2020","journal-title":"Blood Rev"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-024-01569-8","article-title":"Cold-antibody autoimmune hemolytic anemia: its association with neoplastic disease and impact on therapy","volume":"26","author":"Berentsen","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"B42","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3892\/mi.2024.211","article-title":"Cold agglutinin syndrome as a precursor for the diagnosis of low-grade lymphoma: a case report","volume":"5","author":"Dongelli","year":"2025","journal-title":"Med Int (Lond)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.87006","article-title":"A case of cold agglutinin disease with transformation to high-grade lymphoma during sutimlimab treatment","volume":"17","author":"Yamaguchi","year":"2025","journal-title":"Cureus"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1180509","article-title":"The choice of new treatments in autoimmune hemolytic anemia: how to pick from the basket","volume":"14","author":"Berentsen","year":"2023","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.250522","article-title":"Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international study","volume":"106","author":"Fattizzo","year":"2021","journal-title":"Haematologica"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1159\/000366244","article-title":"The effect of erythropoiesis-stimulating agents in patients with therapy-refractory autoimmune hemolytic anemia","volume":"41","author":"Salama","year":"2014","journal-title":"Transfus Med Hemotherapy Offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2023.2218611","article-title":"Complement-directed therapy for cold agglutinin disease: sutimlimab","volume":"16","author":"Broome","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"102732","DOI":"10.1016\/j.eclinm.2024.102732","article-title":"Sustained improvements in patient-reported outcomes after long-term sutimlimab in patients with cold agglutinin disease: results from the CADENZA study open-label extension","volume":"74","author":"R\u00f6th","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B49","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1046\/j.1537-2995.1987.27187121473.x","article-title":"Evidence suggesting the occurrence of C3-independent intravascular immune hemolysis. Reactive hemolysis in vivo","volume":"27","author":"Salama","year":"1987","journal-title":"Transfusion"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12638","article-title":"Lethal autoimmune hemagglutination due to an immunoglobulin A autoagglutinin with Band 3 specificity","volume":"54","author":"Salama","year":"2014","journal-title":"Transfusion"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1770676","article-title":"Case report: Refractory cold agglutinin disease with hypersplenism: efficacy of splenectomy in a patient treated with sutimlimab","volume":"17","author":"Sau","year":"2026","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2991\/chi.k.200706.001","article-title":"Cold agglutinin disease","volume":"2","author":"Gabbard","year":"2020","journal-title":"Clin Hematol Int"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/307093","article-title":"Initiation and regulation of complement during hemolytic transfusion reactions","volume":"2012","author":"Stowell","year":"2012","journal-title":"Clin Dev Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1906515\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:35:52Z","timestamp":1789450552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1906515\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":53,"alternative-id":["10.3389\/fimmu.2026.1906515"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1906515","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"1906515"}}